Sartorius Stedim Biotech (OTCMKTS:SDMHF – Get Free Report) is expected to release its resultson Thursday, July 23rd. Analysts expect the company to post earnings of $1.44 per share and revenue of $906.42 million for the quarter.
Sartorius Stedim Biotech Trading Down 11.1%
Shares of Sartorius Stedim Biotech stock opened at $191.50 on Wednesday. Sartorius Stedim Biotech has a twelve month low of $178.30 and a twelve month high of $264.30. The business’s 50 day simple moving average is $201.40 and its 200-day simple moving average is $208.59.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.
Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.
Featured Articles
- Five stocks we like better than Sartorius Stedim Biotech
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
